Literature DB >> 27512924

Hemostasis biomarkers and risk of sepsis: the REGARDS cohort.

J X Moore1,2, N A Zakai3, M Mahalingam4, R L Griffin3, M R Irvin3, M M Safford5, J W Baddley6, H E Wang1.   

Abstract

Essentials Few studies have investigated the risk of sepsis by baseline hemostasis biomarkers measures. Baseline hemostasis biomarkers and risk of sepsis was examined using case-control study design. Increased fibrinogen, factor IX, and factor XI levels may be associated with risk of sepsis. Hemostasis biomarkers may provide a target for sepsis mitigation or prevention.
SUMMARY: Background Sepsis is a major public health concern, responsible for more than 750 000 hospitalizations and 200 000 annual deaths in the USA. Few studies have investigated the association between baseline measurements of hemostasis biomarkers and the future risk of sepsis. Objective To determine whether hemostasis biomarkers levels measured at baseline in a cohort of community-dwelling participants are associated with the risk of future sepsis events. Methods We performed a nested case-control study within the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. We identified sepsis hospitalizations occurring over a 10-year period. There were 50 incident sepsis cases with baseline measurements of hemostasis (fibrinogen, factor VIII, FIX, FXI, protein C, and D-dimer). Using incidence density sampling, we matched the 50 sepsis cases with 200 controls by age, sex, and race. We used conditional logistic regression to evaluate the association between baseline hemostasis biomarkers and future sepsis events. Results Comparison of 50 sepsis cases with 200 non-sepsis controls showed that sepsis cases had lower education and income, were more likely to live in the stroke belt, had chronic lung disease, and had higher albumin level/creatinine level ratios (ACRs). Individuals with higher baseline fibrinogen levels (adjusted odds ratio [OR] per standard deviation: 1.40, 95% confidence interval [CI] 1.01-1.94), FIX levels ([OR] 1.46, 95% [CI] 1.03-2.07) and FXI levels ([OR]1.52, 95% [CI] 1.04-2.23) were more likely to experience a sepsis event. Conclusion Baseline fibrinogen, FIX and FXI levels are associated with future episodes of sepsis. Hemostasis biomarkers may provide targets for sepsis mitigation or prevention.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  epidemiology; factor IX; factor VIII; factor XI; fibrinogen; sepsis

Mesh:

Substances:

Year:  2016        PMID: 27512924      PMCID: PMC5503746          DOI: 10.1111/jth.13446

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  56 in total

1.  Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1.

Authors:  Asada Leelahavanichkul; Yuning Huang; Xuzhen Hu; Hua Zhou; Takayuki Tsuji; Richard Chen; Jeffrey B Kopp; Jürgen Schnermann; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2011-08-10       Impact factor: 10.612

Review 2.  Review article: coagulation disorders in chronic liver disease.

Authors:  M Peck-Radosavljevic
Journal:  Aliment Pharmacol Ther       Date:  2007-11       Impact factor: 8.171

3.  N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort.

Authors:  Mary Cushman; Suzanne E Judd; Virginia J Howard; Brett Kissela; Orlando M Gutiérrez; Nancy S Jenny; Ali Ahmed; Evan L Thacker; Neil A Zakai
Journal:  Stroke       Date:  2014-04-22       Impact factor: 7.914

4.  An analysis of the use of multiple comparison corrections in ophthalmology research.

Authors:  Carrie Huisingh; Gerald McGwin
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-13       Impact factor: 4.799

5.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

6.  Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis.

Authors:  Damon P Eisen; David Reid; Emma S McBryde
Journal:  Crit Care Med       Date:  2012-06       Impact factor: 7.598

7.  Validating laboratory results in a national observational cohort study without field centers: the Reasons for Geographic and Racial Differences in Stroke cohort.

Authors:  Sarah R Gillett; Rebekah H Boyle; Neil A Zakai; Leslie A McClure; Nancy S Jenny; Mary Cushman
Journal:  Clin Biochem       Date:  2014-08-14       Impact factor: 3.281

8.  Predictive Value of IL-8 for Sepsis and Severe Infections After Burn Injury: A Clinical Study.

Authors:  Robert Kraft; David N Herndon; Celeste C Finnerty; Robert A Cox; Juquan Song; Marc G Jeschke
Journal:  Shock       Date:  2015-03       Impact factor: 3.454

Review 9.  Structural and functional features of factor XI.

Authors:  D Gailani; S B Smith
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

10.  Black-white racial disparities in sepsis: a prospective analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.

Authors:  Justin Xavier Moore; John P Donnelly; Russell Griffin; Monika M Safford; George Howard; John Baddley; Henry E Wang
Journal:  Crit Care       Date:  2015-07-10       Impact factor: 9.097

View more
  2 in total

1.  Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels.

Authors:  Radica Zivkovic Zaric; Jasmina Milovanovic; Nikola Rosic; Dragan Milovanovic; Dejana Ruzic Zecevic; Marko Folic; Slobodan Jankovic
Journal:  Open Med (Wars)       Date:  2018-10-22

2.  Circulating Vitronectin Predicts Liver Injury and Mortality in Children With Sepsis: A Prospective Observational Study.

Authors:  Chunxia Wang; Yun Cui; Huijie Miao; Ting Sun; Ye Lu; Yucai Zhang
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.